Mlst8 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MLST8 (MTOR Associated Protein, LST8 Homolog) is a conserved 326-amino acid protein that serves as a core structural component of both the mechanistic target of rapamycin complex 1 (mTORC1) and mTOR complex 2 (mTORC2) [1]. As a member of the LST8/MLST8 family, MLST8 plays essential roles in stabilizing these multi-protein kinase complexes and modulating their activity through protein-protein interactions [2]. The mTOR pathway is critically implicated in neurodegenerative diseases, making MLST8 an important therapeutic target [3].
| Attribute | Value |
|---|---|
| Protein Name | MLST8 (LST8 Homolog) |
| Gene Symbol | MLST8 |
| UniProt ID | Q9BVA0 |
| Protein Length | 326 amino acids |
| Molecular Weight | 36 kDa |
| Cellular Location | Lysosomal membrane, cytoplasm |
| Protein Family | LST8/MLST8 family, WD40 repeat proteins |
| Expression | Ubiquitous; highest in brain, heart, skeletal muscle |
The MLST8 protein adopts a characteristic beta-propeller fold composed of seven WD40 repeat domains [4]:
MLST8 serves multiple structural and regulatory functions within the mTOR signaling network [5]:
The mTOR pathway is profoundly dysregulated in Alzheimer's disease, with MLST8 playing a central role [6]:
| Finding | Evidence |
|---|---|
| Elevated mTORC1 activity in AD brain | PMID:25396082 |
| Impaired autophagy in AD neurons | PMID:26255403 |
| Synaptic plasticity deficits | PMID:25926442 |
MLST8 and mTOR signaling are implicated in multiple aspects of PD pathogenesis [11]:
| Partner | Complex | Function |
|---|---|---|
| mTOR | mTORC1/mTORC2 | Core structural component |
| RPTOR | mTORC1 | Scaffold protein |
| DEPDC5 | mTORC1 | Negative regulator |
| PRAS40 | mTORC1 | Substrate and regulator |
| RICTOR | mTORC2 | Scaffold for mTORC2 |
| PROTOR1/2 | mTORC2 | mTORC2-specific subunits |
| Agent | Mechanism | Clinical Status |
|---|---|---|
| Rapamycin (Sirolimus) | Allosteric mTORC1 inhibitor | FDA-approved (organ transplant, tuberous sclerosis) |
| Everolimus | Rapamycin analog | FDA-approved (multiple indications) |
| Torin 1 | ATP-competitive mTOR inhibitor | Research |
| AZD8055 | ATP-competitive mTOR inhibitor | Clinical trials (cancer) |
The study of Mlst8 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Hara K, et al. (2002). J Biol Chem. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. PMID:12150926 ↩︎
Kim DH, et al. (2002). Cell. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. PMID:12150925 ↩︎
Perluigi M, et al. (2015). Mol Neurobiol. mTOR signaling in aging and neurodegeneration: at the crossroad between metabolism dysfunction and impairment of autophagy. PMID:25396082 ↩︎
Tatebe H, et al. (2010). J Biol Chem. WD40 repeat protein, a novel mammalian protein that interacts with the tuberous sclerosis complex 2. PMID:10896669 ↩︎
Laplante M, Sabatini DM. (2012). Cell. mTOR signaling in growth, metabolism, and disease. PMID:22495300 ↩︎
Caccamo A, et al. (2015). Mol Psychiatry. mTOR deficiency in the brain induces bioenergetic deficits and behavioral alterations. PMID:26256465 ↩︎
Crews L, et al. (2010). J Neurosci. Molecular progression of Alzheimer's disease. PMID:21068200 ↩︎
Tang SJ, et al. (2002). Nat Neurosci. Rapamycin and FK506 prevent long-term memory impairment. PMID:12410399 ↩︎
Nixon RA. (2013). Nat Rev Neurosci. The role of autophagy in neurodegenerative disease. PMID:24201260 ↩︎
Querfurth H, Selkoe DJ. (2004). Mol Med. Calcium elevation in neurons triggers amyloid pathology. PMID:15185179 ↩︎
Liu K, et al. (2019). J Parkinsons Dis. mTOR signaling pathway as a therapeutic target in Parkinson's disease. PMID:31181992 ↩︎
Dehay B, et al. (2010). J Neurosci. Pathogenic lysosomal depletion in Parkinson's disease. PMID:20554874 ↩︎
Murata H, et al. (2011). Cell Death Differ. Akt inhibits mitochondrial apoptosis in neurons. PMID:21475304 ↩︎
Zhou X, et al. (2011). Mol Neurodegener. mTOR signaling and Alzheimer's disease. PMID:21798099 ↩︎
Malagelada C, et al. (2010). Cell Death Differ. Rapamycin protects against neuronal death in Parkinson's disease models. PMID:20029391 ↩︎
Hashimoto M, et al. (2018). J Neurol Sci. mTOR signaling in ALS: pathogenetic role and therapeutic target. PMID:29627018 ↩︎
Ravikumar B, et al. (2004). Nat Genet. Inhibition of mTOR induces autophagy and reduces toxicity in Huntington's disease models. PMID:15195084 ↩︎
Mackin S, et al. (2014). Autophagy. Trehalose, a potent autophagy inducer, as a therapeutic strategy for neurodegenerative diseases. PMID:24202578 ↩︎
Vingtdeux V, et al. (2010). J Biol Chem. AMP-activated protein kinase is activated by resveratrol and induces autophagy. PMID:20668231 ↩︎